Abbott completed its $21 billion acquisition of Exact Sciences on March 23, 2026, closing one of the largest healthcare deals of the year and positioning Abbott as the leading company in cancer screening diagnostics in the United States. The deal, first announced in November 2025, received all necessary regulatory clearances and was finalized at $105 per share in cash.
- Abbott closed its $21 billion acquisition of Exact Sciences on March 23, 2026, paying $105 per share in cash after receiving all regulatory clearances.
- The deal is expected to add approximately $3 billion in incremental sales to Abbott’s revenue in 2026, with Exact Sciences growing at a high teens organic rate.
- Abbott now leads the $60 billion U.S. cancer screening and precision oncology diagnostics market, with total diagnostics sales exceeding $12 billion annually as of today.
Details of the Abbott Exact Sciences Acquisition
The total enterprise value of the transaction is approximately $23 billion, which includes Exact Sciences’ estimated $1.8 billion in net debt. Abbott Chairman and CEO Robert B. Ford said the addition of Exact Sciences enhances Abbott’s growth profile and strengthens its leadership position in diagnostics.
Exact Sciences brings a portfolio of cancer screening and precision oncology products that generated more than $3 billion in trailing 12-month revenue as of late 2025. The company’s flagship product, Cologuard, is a noninvasive stool-based DNA test for colorectal cancer screening that has become a widely adopted alternative to traditional colonoscopies for average-risk patients. Exact Sciences also makes Oncotype DX for breast cancer treatment guidance, Oncodetect for molecular residual disease monitoring, and Cancerguard, a multi-cancer early detection blood test.
Exact Sciences employs approximately 7,000 people. Under the terms of the deal, the company will operate as a subsidiary of Abbott going forward.
Why Abbott Bought Into Cancer Diagnostics
Cancer screening and precision oncology diagnostics represent a $60 billion market in the United States alone, according to Abbott’s estimates. Before this acquisition, Abbott’s diagnostics business focused primarily on core laboratory testing, point-of-care devices, and rapid diagnostics. The Exact Sciences deal fills a gap that Abbott could not easily close through organic development.
The cancer diagnostics sector has been one of the fastest growing segments in healthcare, driven by rising adoption of liquid biopsy technology, multi-cancer early detection tests, and increasing emphasis on preventive screening. Exact Sciences’ high teens organic growth rate made it one of the most attractive acquisition targets in the space. The deal follows a broader wave of consolidation in diagnostics, as large companies pursue billion-dollar acquisitions to lock in competitive advantages in fast-moving markets.
Impact on the Healthcare and Startup Landscape
Abbott’s entry as the dominant cancer diagnostics company will reshape the competitive landscape for smaller players in the space. Startups developing liquid biopsy, early detection, and precision oncology tools now face a significantly larger incumbent with deep distribution networks, regulatory expertise, and the financial resources to outspend on R&D and commercialization.
For healthcare founders, the deal signals that cancer diagnostics remains one of the most valuable categories in medtech. Companies that have built differentiated screening or detection products, particularly in early-stage cancer identification, are likely to attract attention from strategic acquirers and venture investors. The deal also validates the trajectory of fast-growing startups raising hundreds of millions to scale in sectors where large incumbents are willing to pay premium multiples for market leadership.
Abbott expects the acquisition to accelerate its 2026 sales growth by approximately 0.5 percent, though it will dilute adjusted earnings per share by about $0.20 in the near term. Abbott trades on the New York Stock Exchange under the ticker ABT.
Frequently Asked Questions
How Much Did Abbott Pay for Exact Sciences?
Abbott acquired Exact Sciences for approximately $21 billion in equity value, paying $105 per share in cash. The estimated enterprise value of the deal is $23 billion, including Exact Sciences’ $1.8 billion in net debt.
What Products Does Exact Sciences Make?
Exact Sciences develops cancer screening and diagnostic tests, including Cologuard for colorectal cancer screening, Oncotype DX for breast cancer treatment decisions, Oncodetect for molecular residual disease monitoring, and Cancerguard, a multi-cancer early detection blood test.
What Does the Abbott Exact Sciences Deal Mean for the Diagnostics Industry?
The acquisition makes Abbott the dominant player in the $60 billion U.S. cancer screening and precision oncology diagnostics market. Abbott’s total diagnostics revenue will exceed $12 billion annually, and the combined company will have the scale to accelerate development of next-generation cancer detection tools.
